LANXESS India wins awards from Indian Chemical Council EP News Bureau Oct 5, 2020 LANXESS India wins awards from Indian Chemical Council
DRL joins SBTi and sets 2030 GHG emission targets EP News Bureau Oct 5, 2020 The company is the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to further…
Piramal Glass appoints Sudip Mazumder as Global Chief Digital & Information Officer EP News Bureau Oct 5, 2020 Piramal Glass has adopted digital interventions with state-of-the-art technologies across the value chain since the last four…
COVAXIN to boost immune response, longer-lasting immunity with ViroVax’s adjuvant EP News Bureau Oct 5, 2020 Bharat Biotech has announced its novel coronavirus vaccine COVAXIN approved for human trials, will use adjuvant Alhydroxiquim-II…
Govt to utilise 400-500 mn COVID-19 vaccine doses covering 20-25 cr people by July 2021: Dr Vardhan EP News Bureau Oct 4, 2020 States have been advised to send details of priority population groups by end of October
Marksans Pharma expands recalls of metformin hydrochloride tablets EP News Bureau Oct 4, 2020 It is due to NDMA content in some lots that exceed the acceptable daily intake limit of 96ng/day
Exim Bank study highlights priority focus areas, policy initiatives for sectors including pharma EP News Bureau Oct 3, 2020 The study titled ‘Domestic Constraints for Exports in Select Sectors’, analyses and highlights policy constraints and common areas…
Dr Reddy’s launches generic sapropterin dihydrochloride tablets for oral use in US EP News Bureau Oct 3, 2020 They are indicated to reduce blood phenylalanine levels in adult and paediatric patients with hyperphenylalaninemia due to…
Biopharma more optimistic about 2020 revenue: GlobalData EP News Bureau Oct 3, 2020 Employee safety remains the primary business concern across all geographies, followed by the pandemic’s impact on supply chains
Bristol Myers Squibb gets US FDA approval for Opdivo + Yervoy to treat unresectable MPM EP News Bureau Oct 3, 2020 The approval marks the third indication for Opdivo + Yervoy-based treatments in thoracic cancers and seventh indication overall